Brought to you by 
BMS and Liposome Co. in cancer deal
13 Dec 1999
Executive Summary
The Liposome Co. (cancer and related diseases) and Bristol-Myers Squibb Co. will collaborate on the production of clinical trials designed to evaluate the safety and efficacy of the former's Evacet in combination with the latter's Taxol (paclitaxel) for the treatment of metastatic breast cancer.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
- Liposomes
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BMS and Liposome Co. in cancer deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice